Today's Daily Dose brings you news about publication of AveXis' promising data of AVXS-101 in patients with spinal muscular atrophy Type 1 in NEJM; stellar Q3 results of Exelixis and Neurocrine, and failure of Momenta/Mylan's biosimilar drug trial.
from RTT - Biotech http://ift.tt/2h4PIRX
via IFTTT
No comments:
Post a Comment